184 related articles for article (PubMed ID: 25150257)
21. Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas.
Paik JH; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
BMC Cancer; 2014 Dec; 14():911. PubMed ID: 25472725
[TBL] [Abstract][Full Text] [Related]
22. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
23. Bcl-2, Bcl-6, and the International Prognostic Index are prognostic indicators in patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy.
Maeshima AM; Taniguchi H; Fukuhara S; Morikawa N; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Cancer Sci; 2012 Oct; 103(10):1898-904. PubMed ID: 22783941
[TBL] [Abstract][Full Text] [Related]
24. High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy.
Cardesa-Salzmann TM; Colomo L; Gutierrez G; Chan WC; Weisenburger D; Climent F; González-Barca E; Mercadal S; Arenillas L; Serrano S; Tubbs R; Delabie J; Gascoyne RD; Connors JM; Mate JL; Rimsza L; Braziel R; Rosenwald A; Lenz G; Wright G; Jaffe ES; Staudt L; Jares P; López-Guillermo A; Campo E
Haematologica; 2011 Jul; 96(7):996-1001. PubMed ID: 21546504
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial.
Ribera JM; Oriol A; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M;
Br J Haematol; 2008 Feb; 140(4):411-9. PubMed ID: 18162120
[TBL] [Abstract][Full Text] [Related]
27. Infusional CDE with rituximab for the treatment of human immunodeficiency virus-associated non-Hodgkin's lymphoma: preliminary results of a phase I/II study.
Tirelli U; Spina M; Jaeger U; Nigra E; Blanc PL; Liberati AM; Benci A; Sparano JA
Recent Results Cancer Res; 2002; 159():149-53. PubMed ID: 11785839
[TBL] [Abstract][Full Text] [Related]
28. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
29. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
Dunleavy K; Little RF; Pittaluga S; Grant N; Wayne AS; Carrasquillo JA; Steinberg SM; Yarchoan R; Jaffe ES; Wilson WH
Blood; 2010 Apr; 115(15):3017-24. PubMed ID: 20130244
[TBL] [Abstract][Full Text] [Related]
30. Interventions for previously untreated patients with AIDS-associated non-Hodgkin's lymphoma.
Martí-Carvajal AJ; Cardona AF; Lawrence A
Cochrane Database Syst Rev; 2009 Jul; (3):CD005419. PubMed ID: 19588373
[TBL] [Abstract][Full Text] [Related]
31. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma.
Hoffmann C; Wolf E; Fätkenheuer G; Buhk T; Stoehr A; Plettenberg A; Stellbrink HJ; Jaeger H; Siebert U; Horst HA
AIDS; 2003 Jul; 17(10):1521-9. PubMed ID: 12824790
[TBL] [Abstract][Full Text] [Related]
32. [Non-Hodgkin lymphomas with systemic presentation in patients with HIV infection. Clinical and prognostic factors in a series evaluated before the introduction of the highly active antiretroviral therapy (HAART)].
Segura Huerta A; López Tendero P; Romera Barroso B; Yuste Izquierdo AL; Gironés Sarrió R; Pérez Fidalgo JA; Gómez Codina J; López Aldeguer J
Rev Clin Esp; 2004 Jun; 204(6):303-7. PubMed ID: 15171891
[TBL] [Abstract][Full Text] [Related]
33. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
34. AIDS-lymphoma (ARL): one more step along the way.
Levine AM
Blood; 2013 Nov; 122(19):3244-6. PubMed ID: 24203926
[TBL] [Abstract][Full Text] [Related]
35. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story.
Bari A; Marcheselli L; Sacchi S; Marcheselli R; Pozzi S; Ferri P; Balleari E; Musto P; Neri S; Aloe Spiriti MA; Cox MC
Ann Oncol; 2010 Jul; 21(7):1486-1491. PubMed ID: 19920060
[TBL] [Abstract][Full Text] [Related]
36. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P
Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561
[TBL] [Abstract][Full Text] [Related]
37. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma.
Navarro JT; Ribera JM; Oriol A; Romeu J; Sirera G; Mate JL; Batlle M; Xicoy B; Grau J; Millá F; Feliu E
Leuk Lymphoma; 2002 Sep; 43(9):1837-42. PubMed ID: 12685841
[TBL] [Abstract][Full Text] [Related]
38. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
39. Serbian lymphoma study group (SLG): the prognosis of AIDS-related non-Hodgkin's lymphoma.
Djunic I; Jevtovic DL; Ranin J; Salemovic D; Tomin D; Mihaljevic B
Biomed Pharmacother; 2008 Jan; 62(1):12-5. PubMed ID: 17629445
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma.
Boué F; Gabarre J; Gisselbrecht C; Reynes J; Cheret A; Bonnet F; Billaud E; Raphael M; Lancar R; Costagliola D
J Clin Oncol; 2006 Sep; 24(25):4123-8. PubMed ID: 16896005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]